Dear All,

-- Please do not donate, we just need your signature. Thanks!
-- Eventually we all die in different ways, but hopefully we die with a heart filled with appreciation and warmth: this world has been kindly trying to save us.

My name is Hongyan Yang, and I am writing to you today to humbly ask for your help in saving my husband's life.

My husband, a 50-year-old father, husband, and brilliant individual, is battling metastatic osteosarcoma. This rare and aggressive cancer spread to his lungs a year ago. Despite undergoing many cycles of chemotherapy with different medicines and various radiotherapies at UCSD Health with additional consultations at Mayo Clinic, MD Anderson Cancer Center, and Sarah Cannon Research Institute, his tumors continue to grow. He has recently experienced coughing blood, pleural effusions, and a pneumothorax, and time is running out.

We have discovered an investigational drug, GSK5764227 (also known as HS20093 or B7H3 ADC), which has shown promising anti-tumor activity in two clinical trials (ClinicalTrials.gov Identifiers: NCT05276609; NCT05830123) for patients like my husband. GSK itself acknowledged the urgent need for new treatments in this area in a January 2025 press release, stating, "There is an urgent unmet medical need with no approved treatment options once the cancer returns a second time, and chemotherapy provides limited benefit in this setting." GSK5764227 has also received Breakthrough Therapy designation, supported by data from the open-label, phase 2 ARTEMIS-002 trial (ClinicalTrials.gov Identifier: NCT05830123), which evaluated the safety and efficacy of GSK5764227 in patients with relapsed/refractory osteosarcoma or other sarcomas who have progressed on first-line systemic treatment.

While the clinical trial for GSK5764227 is not a viable option for us, my husband's condition fully meets GSK's criteria for compassionate use listed in their position paper, "Treatment Use of Unlicensed Medicines GSK Public Policy Position July 2024", as confirmed by his oncologist. We urgently requested access to the drug, but GSK denied our request (GSK ID 12377), citing "without sufficient evidence to believe the benefit to the patient justifies the risk, we do not feel that compassionate use of GSK5764227 is possible to justify." This decision has broken our hearts!

Without this drug, his expected survival time could be months; there is no risk greater than death. We fully understand the risks and responsibilities associated with choosing an investigational drug, and while the outcome is not predictable, any potential benefit would bring immense hope to our family.

Therefore, we kindly request that GSK grant compassionate use of this drug to save his life. Your approval would be greatly appreciated by his family and would send a strong humanistic signal to our society.

We are asking for your support. Please sign and share this petition to help us open the door to save a life.

With gratitude,
Hongyan Yang